Feb 18th 2013 - Edison Investment Research today published a report on quickview entitled "Data To Drive A Deal". In summary, the report says:
Data from five controlled trials of MolMed’s selective vascular targeting agent NGR-hTNF are due to be announced during 2013, which could trigger a partnership and help determine future Phase III development in solid tumours. A partnership is key to unlocking NGR-hTNF’s value and is in turn central to MolMed’s investment case. If Phase III data due in H2 in the initial indication of mesothelioma are positive, NGR-hTNF could be filed shortly thereafter. MolMed is also planning to file TK for EU conditional approval in high-risk leukaemia during 2013.
Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »